More so than most of its European neighbors, Spain at the turn of the 21 st century thought it had successfully relegated diphtheria to the past: the country had not seen a case of diphtheria since 1986. 1 Not, that is, until a 6-year old Catalonian boy was diagnosed with the disease in May 2015. Although diphtheria has been a curable disease since the development of diphtheria antitoxin (DAT) in the 1890s and its widespread manufacture by the early 20 th century, scarcely a month after his diagnosis, the child succumbed to the disease known a century earlier as "the strangling angel." Ten months later, a second native-born Western European childthis time in Belgium-perished after contracting diphtheria.
The Spanish and Belgian cases point towards a larger question: what happens to an essential medicine after the epidemic it treats has passed? Diphtheria is a treatable disease, but the window from first symptoms to irreversible damage is short, and delay in treatment can diminish chances of survival. With physicians rarely encountering the disease that today causes less than 5,000 cases annually worldwide, 2 and DAT stocks being low or non-existent, delayed diagnosis and DAT procurement contributed to the death of the two European children. Their case clearly demonstrates that any disruption to immunization can quickly become fatal in countries in which the overall incidence of the disease has become negligible.
Although it is on the World Health Organization's Essential Medicines list, neither
Spain nor Belgium had stockpiles of DAT on hand when these cases hit. 3 Both countries had to reach out to EU member states and the WHO to locate supplies of diphtheria antitoxin. Ironically, it was the very successes with diphtheria prevention (especially following >95% vaccination rates with diphtheria toxoid) that had eroded the market for DAT in Europe and North America-and with it, the availability of treatment.
In Europe, the international concern sparked by the death of the Spanish and Belgian children is reminiscent of an earlier set of outbreaks, at the very end of the Cold War.
European states received a stark reminder of the ferocity of diphtheria when, in the early 1990s news of escalating outbreaks started emerging from countries of the former Soviet Union. Political turmoil in these states brought a rise in anti-vaccination sentiments, disruption of health services including immunization programmes and a mass movement of people. Between 1990 and 1998, the 157,000 cases (including 5,000 deaths) in Russia and the Newly Independent States accounted for over 80% of diphtheria cases worldwide. 4 The epidemic put into motion institutional frameworks in Europe: the foundations of a diphtheria surveillance network, now operating under European Centre for Disease Control (ECDC). Despite the stark contrast between low case fatality rates in Russia, where DAT was readily available, and high ones the Newly Independent States, where it was not, most of the scientific discussion following the outbreak focused on prevention, with little attention paid to maintaining access to the antitoxin. 56 We should not be quick to dismiss the significance of the post-Soviet experience.
What had been a country with solid health surveillance and high vaccination rates for decades quickly became a site of a severe epidemic. The outbreak in countries of the former Soviet Union brings to focus the frailty of public health systems in the face of political breakdown, and the force and speed with which long-forgotten diseases can re-emerge. Concentrating on immunisation alone might not be sufficient in what seems to be a rapidly changing global political structure.
In the rest of Europe incidence of diphtheria remained consistently low and vaccination coverage remained high in the decades since the post-Soviet outbreak.
This sustained absence of the disease has had profound effects on industry interest in antitoxin production. While in the early twentieth century a host of national institutions and private companies competed to produce DAT, in the second half of the century sites of production dwindled to a handful of countries. By the mid-2010s pharmaceutical companies and state institutions in Europe ceased DAT production, with Bulgaria remaining the only manufacturer for mostly an internal, national market. 7 Today the continent is left without access to DAT produced in Europe. The global production of diphtheria antitoxin now maps onto countries where the disease is still, or until recently had been endemic: Instituto Butantan in Brazil, a complex of Indian companies, and Mikrogen in Russia. names Albenza and Daraprim, respectively). 12 Although diphtheria antitoxin in the U.S. has not been subject to analogous price-gouging, these cases collectively underscore the hazards of assuming that-after an epidemic recedes-the older effective medicines that helped to keep it at bay will simply remain cheap and available as part of a well-archived clinical and public health armamentarium.
With the increased control of diphtheria on three continents, the success of prevention can paradoxically lead to high costs for those unfortunate individuals who nonetheless still contract it. This is due not only to changes in pharmaceutical markets, but also on the paradoxical effect of successful prevention programs on the practice of diagnosis.
In both Belgium and Spain, delay in treatment owed less to the days that it took for the nations to request DAT from EU member states, but in the longer and more plodding process from initial presentation to positive diagnosis of a disease thought long-departed from Europe. While according to the WHO's guidelines, DAT should be administered upon suspicion of diphtheria before laboratory confirmation, 13 these recommendations are unfeasible when DAT is unavailable and where access to limited regional or global stocks needs to follow diplomatic routes.
In the past 50 years, with the exception of a handful of countries, 14 No organization today is playing the part the Red Cross played a half-century ago.
The sense of urgency of access to therapeutics might be very similar, but as an overall public health problem, the emergency of an epidemic is entirely missing. Health Organization and cooperation among its member states, we may well soon face an increasing struggle to keep children from dying from a disease that has been treatable since 1890.
